Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04356040 · ClinicalTrials.gov registry record · NA
TactiFlex Paroxysmal Atrial Fibrillation IDE Trial
A NA study of Paroxysmal Atrial Fibrillation, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 355
- Enrollment target
- 20
- Study locations
NCT04356040 is a NA study of Paroxysmal Atrial Fibrillation that has completed, run by Abbott Medical Devices. The registered enrollment target is 355 participants, below the 844-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT04356040, a NA study of Paroxysmal Atrial Fibrillation, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 355 participants
- Enrollment target
- 20
- Study locations
Study Summary
Prospective non-randomized parallel-assignment multi-center clinical investigation. The study design includes two subject cohorts: 1) Paroxysmal Atrial Fibrillation Main Study, and 2) Paroxysmal Atrial Fibrillation High Standard Power Substudy. Subjects in the main study cohorts are to be treated using the full range of ablation power settings in the Instructions For Use. Subjects in the High Standard Power Substudy are to be treated in the upper end of the recommended ablation power settings (40-50 Watts).
Conditions Studied
Interventions
- DEVICE TactiFlex SE
- DEVICE TactiFlex SE - High Standard Power
Study Locations (20)
California
- Mills-Peninsula Medical Center - Burlingame
- Scripps Health - La Jolla
- University of California at San Diego (UCSD) Medical Center - San Diego
Arkansas
- St. Bernards Medical Center - Jonesboro
- Arkansas Heart Hospital - Little Rock
Idaho
- St. Luke's Regional Medical Center - Boise
- Kootenai Heart Clinics - Coeur d'Alene
Mississippi
- Jackson Heart Clinic - Jackson
- North Mississippi Medical Center - Tupelo
Alabama
- Affinity Cardiovascular Specialists, LLC - Birmingham
Colorado
- South Denver Cardiology Associates PC - Littleton
Florida
- AdventHealth Orlando - Orlando
Georgia
- Piedmont Athens Regional Medical Center - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2020-06-29 |
| Est. Completion | 2022-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04356040
The ClinicalTrials.gov registry entry for NCT04356040 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 844-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (58% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which TactiFlex SE is the first listed.
NCT04356040 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Arkansas, Idaho.
Frequently Asked Questions
What is clinical trial NCT04356040 about?
NCT04356040 is a clinical study titled "TactiFlex Paroxysmal Atrial Fibrillation IDE Trial". Prospective non-randomized parallel-assignment multi-center clinical investigation. The study design includes two subject cohorts: 1) Paroxysmal Atrial Fibrillation Main Study, and 2) Paroxysmal Atrial Fibrillation High Standard Power Substudy. Subjects in the main study cohorts are to be treated us...
What is the current status of trial NCT04356040?
This trial is currently completed. It is a NA study. The enrollment target is 355 participants. The study started on 2020-06-29. Estimated completion is 2022-07-01.
What conditions does trial NCT04356040 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT04356040?
The interventions under investigation include: TactiFlex SE (DEVICE), TactiFlex SE - High Standard Power (DEVICE).
Who is sponsoring clinical trial NCT04356040?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04356040 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
RECRUITING · NA
-
POLARx Post Approval Study (POLARx PAS)
RECRUITING · NA
-
Treatment of PAF With the Synaptic System
ACTIVE NOT RECRUITING · NA
-
Meditation and Education That is Nurse Delivered for Symptom Management in Paroxysmal Atrial Fibrillation (PAF)
ACTIVE NOT RECRUITING · NA
-
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.